RNA interference Archives -

Scopus BioPharma has licensed a gene-silencing drug from California’s City of Hope hospital that is due to start

Scopus Bio preps trials of gene-silencing immuno-oncology drug

https://pharmaphorum.com/news/scopus-bio-preps-trials-of-gene-silencing-immuno-oncology-drug/

Alnylam could be weeks away from getting its second RNA interference drug approved in Europe, after a CHMP

Alnylam gets CHMP backing for second gene-silencing drug Givlaari

https://pharmaphorum.com/news/alnylam-gets-chmp-backing-for-second-gene-silencing-drug-givlaari/

After years where RNA interference research was in the doldrums, Alnylam is on a roll and is preparing

Alnylam to file rare kidney disease drug after trial win

https://pharmaphorum.com/news/alnylam-to-file-rare-kidney-disease-drug-after-phase-3-win/

Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront

Roche swoops on Dicerna’s gene-silencing hepatitis B drug

https://pharmaphorum.com/news/roche-swoops-on-dicernas-gene-silencing-hepatitis-b-drug/

Cardiologists only had to wait a few days after The Medicines Company teased top-line results with its cholesterol-lowering

TMC’s inclisiran impresses at ESC, but will it surpass PCSK9 rivals?

https://pharmaphorum.com/news/tmcs-inclisiran-impresses-at-esc-but-will-it-surpass-pcsk9-rivals/

Biotech axes revusiran due to safety concerns.

Alnylam plunges after deaths in rare disease trial

https://pharmaphorum.com/news/anylam-ends-heart-drug-development/

RNA interference